Noble Financial started coverage on shares of Nutriband (NASDAQ:NTRB – Free Report) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $13.00 target price on the stock.
Nutriband Stock Up 40.9 %
NASDAQ:NTRB opened at $7.34 on Wednesday. Nutriband has a 52 week low of $2.22 and a 52 week high of $9.60. The stock’s fifty day moving average is $4.44 and its two-hundred day moving average is $5.40. The stock has a market capitalization of $81.52 million, a price-to-earnings ratio of -10.34 and a beta of 0.99. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.01.
Nutriband (NASDAQ:NTRB – Get Free Report) last posted its earnings results on Tuesday, December 3rd. The company reported ($0.12) earnings per share (EPS) for the quarter. Nutriband had a negative return on equity of 54.49% and a negative net margin of 338.51%.
Nutriband Company Profile
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
Further Reading
- Five stocks we like better than Nutriband
- The 3 Best Fintech Stocks to Buy Now
- Oracle Announces Game-Changing News for the AI Industry
- How Can Investors Benefit From After-Hours Trading
- Netflix Adds 19 Million Subscribers, Growth Is Far From Over
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Tempus AI: A Game-Changer in AI-Powered Healthcare
Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.